Feasibility of liver stiffness measurement in morbidly obese patients undergoing bariatric surgery using XL probe
- 16 June 2016
- journal article
- research article
- Published by Taylor & Francis Ltd in Scandinavian Journal of Gastroenterology
- Vol. 51 (10), 1263-1268
- https://doi.org/10.1080/00365521.2016.1191084
Abstract
Objective: Prevalence of non-alcoholic fatty liver disease is rising in the Western world and reaches up to 90% in patients undergoing bariatric surgery. Fibroscan® as a non-invasive tool for liver stiffness measurement (LSM) has several limitations in morbidly obese patients. Only few data exist about the technical feasibility and accuracy of LSM in these patients. We aimed to analyse the feasibility of LSM by Fibroscan® in bariatric patients. Materials and methods: In morbidly obese patients, LSM was performed using XL probe. Measurements were termed reliable if 10 successful measurements with a success rate ≥60% and an interquartile range/median (IQR/M) 0.3, and they were termed failed if they were neither reliable nor unreliable. Results: A total of 149 patients were included (87 with liver biopsies); mean BMI was 51.6 ± 8.5 kg/m2. In 41% LSM using XL-probe was reliable, in 22% unreliable and in 37% failed. Failed LSM was significantly more frequent in patients with higher BMI compared to reliable and unreliable measurements (p < 0.05). In patients with failed measurement, sonographic paramedian and intercostal distances were significantly higher compared to reliable measurements. All three patients with F4 fibrosis could successfully be differentiated by LSM from patients without fibrosis. Conclusions: LSM with XL probe is feasible in almost two-thirds of morbidly obese patients with a BMI ≥50 kg/m2. Reliable prediction of advanced fibrosis appears to be possible even if formal criteria of successful measurements are not met.Keywords
This publication has 29 references indexed in Scilit:
- Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver DiseaseGastroenterology, 2015
- Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐upHepatology, 2014
- The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological AssociationHepatology, 2012
- Independent Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease in the US PopulationClinical Gastroenterology and Hepatology, 2012
- Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008Clinical Gastroenterology and Hepatology, 2011
- Fibrosis in alcoholic and nonalcoholic steatohepatitisBest Practice & Research Clinical Gastroenterology, 2011
- Non‐alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosisInternational Journal of Cancer, 2010
- The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitisHepatology, 2010
- The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver diseasePowell EE, Cooksley WGE, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years [Hepatology 1990; 11:74–80]Journal of Hepatology, 2004
- Transient elastography: a new noninvasive method for assessment of hepatic fibrosisJapanese Journal of Clinical Oncology, 2003